MicroRNAs (miRNAs) as small non-coding RNAs with 21-23 nucleotides act via negatively regulating gene expression by binding with the 3′ UTR of cognate mRNA targets. 10 Accumulating evidence shows that dysregulation of miRNAs is involved in multiple cellular processes of GC including cell proliferation, migration and metastasis, [11] [12] [13] of which miR-149 and miR-200c inhibit tumour metastasis in hepatocellular carcinoma (HCC) and breast cancer by targeting PPM1F 14, 15 and uncover the regulation link between PPM1F and miRNAs in cancer.
However, in the present study, TCGA data and tissue microarray analysis indicated that PPM1F expression was downregulated in GC and correlated with tumour recurrence of the patients. Taken account into no significant alterations in genetic and epigenetic dysregulation for PPM1F in GC, miR-590-3p was further identified to display an oncogenic role by targeting PPM1F and acted as an independent prognostic factor for tumour recurrence of patients with GC.
| MATERIAL S AND ME THODS

| Clinical data
The clinicopathological and prognostic data for 415 cases of GC patients and 33 adjacent normal tissues as well as the relative expression levels of PPM1F and miRNAs (has-miR-590-3p, has-miR-186-5p, has-miR-200b, has-miR-200c and has-miR-429) were downloaded from The Cancer Genome Atlas 2015 RNA-sequencing database (https://genome-cancer.ucsc.edu). The protocols used in our study were approved by the Ethics Committee of Shanghai Sixth People's
Hospital. The clinicopathological characteristics of 308 GC patients for PPM1F expression were summarized in Table S1 .
| Immunohistochemistry (IHC) analysis
The tissue microarray of GC was purchased from the Outdo Biotech Co, LTD (HStmA030PG03, Shanghai, PR, China), and it included 15 GC samples and corresponding 15 adjacent normal tissues. The expression or cellular localization of PPM1F in GC tissue cells was determined by IHC analysis. The GC tissues were stained for anti-PPM1F (ab156222, Rabbit polyclonal antibody, Abcam, Cambridge, MA, USA) and its expression level was quantified as previously described. 16 
| Identification of miRNAs in cancer tissues
The miRNAs that target 3′UTR of PPM1F gene were identified in cancer tissues by using the StarBase v2.0 (http://starbase.sysu.
edu.cn) under the strictly incorporated conditions with 2 prediction algorithms (TargetScan 7.1 and microRNA. org) and very high stringency (>5). heat-inactivated foetal bovine serum (FBS), 100 U/mL of penicillin and 100 μg/mL of streptomycin (HyClone) in a humidified atmosphere containing 5% CO2 at 37°C.
| Cell culture
| Quantitative real-time PCR (qRT-PCR)
Total RNA of AGS and MKN-28 cells was collected by using TRIzol and reverse transcription was conducted by using M-MLV and cDNA amplification by using the SYBR Green Master Mix kit (Takara, Otsu, Japan). In addition, total RNA for miRNAs was isolated by using a High Pure miRNA isolation kit (Roche) and RT-PCR using a TaqMan
MicroRNA Reverse Transcription kit (Life Technologies). A miScript
Primer Assay (QIAGEN) was used for the miR-193a and U6. Data were analysed using the comparative Ct method (2 −△△Ct ). Three separate experiments were performed for each clone. The primers were listed in Table S2 .
| Western blotting analysis
AGS and MKN-28 cells were harvested and their proteins were extracted by using lysis buffer. The primary antibody against PPM1F
(ab156222, Rabbit polyclonal antibody, Abcam, Cambridge, MA, USA) was diluted at a ratio of 1:1000 and the second antibody
Goat anti-Rabbit IgG H&L (HRP) (ab6721, Abcam, Cambridge, MA, USA) was diluted at a ratio of 1:10000 according to the instructions. Western blotting analysis was conducted as previously described. 16 
| Luciferase reporter assay
Luciferase reporter assay was performed as previously described. 
| Cell migration assay
| Cell viability, colony formation and transwell invasion assays
Cell viability, colony formation and transwell assays were performed as previously described. 16 curves were analysed with the Kaplan-Meier method and log-rank test. Univariate analysis and multivariate models were performed by using a Cox proportional hazards regression model. P < .05 was considered statistically significant.
| Statistical analysis
| RE SULTS
| Downregulation of PPM1F expression is correlated with tumour recurrence of GC patients
Distinct from the previous studies indicating that PPM1F is upregulated in HCC and breast cancer, 7, 12, 13 analysis ( Figure 1B ). IHC analysis showed that PPM1F was mainly localized in the cytoplasm and its positive rate was much lower in GC tissues than the adjacent normal tissues (53.33% vs 86.67%, P = .021) ( Figure 1C ). These findings suggested that loss of PPM1F expression was a frequent event in GC.
Moreover, according to the OS time, OS status and PPM1F expression level, we gained the cut-off value (1.21) of PPM1F
( Figure 1D ) in GC samples (n = 308), and divided the patients into 2 groups: PPM1F high expression and PPM1F low expression ( Figure 1E ). ROC curve and AUC were used to calculate the sensitivity and specificity of PPM1F expression, which demonstrated that the sensitivity, specificity and AUC of PPM1F were respectively 33.9%, 81.8% and 0.55% ( Figure 1D ), indicating that PPM1F expression might be a potential marker for GC patients.
We further analysed the correlation of PPM1F expression with the clinicopathological characteristics and prognosis of GC patients and found that PPM1F expression was associated with the age (P = .033), but had no correlation with the other factors such as gender, pathological stage and TNM stage (each P > .05, Table S3 ).
Kaplan-Meier analysis revealed that the patients with PPM1F low expression harboured higher tumour recurrence rate ( Figure 1F was an independent prognostic factor for tumour recurrence of GC patients (Table 1) .
| PPM1F displays a negative correlation with miR-590 expression in GC samples
To uncover the reason for PPM1F downregulation in GC, we evaluated the genetic or epigenetic dysregulation of PPM1F expression in GC (n = 370), which indicated that PPM1F had no significant alterations at the genetic ( Figure S2A ,B) and methylation levels ( Figure S2C ) and gene amplification, deletion, mutation, copy number deletion and methylation modification could not account for the downregulation of PPM1F in GC.
Additionally, it is known that miRNAs act by negatively regulating their target gene. 10 To illustrate whether PPM1F expression is regulated by miRNAs, the prediction tools microRNA. org and TA B L E 1 Cox regression analysis of PPM1F expression as a recurrence predictor recurrence tendency in GC patients ( Figure S3B,C) . Thus, only miR-590 high expression ( Figure 2B ,C) was consistent with the previously reported results 22 and was selected for further investigation.
| PPM1F was verified as a target of miR-590 in GC cells
Having demonstrated the negative correlation of PPM1F expression with mir-590 in GC samples ( Figure 2D4 ), we further verified whether PPM1F is a target of miR-590 in GC. We first detected the expression levels of miR-590 in GC cell lines by qRT-PCR, indicating that miR- However, the luciferase activity of Mut 3′UTR of PPM1F was not significantly influenced by miR-590 mimic or inhibitor in GC cells.
| PPM1F rescued the cell viability and colony formation induced by miR-590
To further investigate the effects of miR-590 on PPM1F expression in GC cells, we conducted the MTT and cell colony formation assays. First, the transfection efficiency of PPM1F overexpression in AGS cells or si-PPM1F in MKN-28 cells was determined by qRT-PCR ( Figure 4A ) and Western blotting analysis ( Figure 4B ). 
| PPM1F counteracted the cell migration and invasion caused by miR-590
We also performed the wound healing and transwell assays to ob- 
| Increased expression of miR-590 was positively associated with tumour recurrence of GC patients
Having defined the increased expression of miR-590 ( Figure 2B,C) and its negative correlation with PPM1F expression ( Figure 2D4 ) in GC samples, we further analysed the relationship between its expression with clinicopathological features and prognosis of the patients with GC. According to the OS time, OS status and miR-590 expression level, the cut-off value (3.763) of miR-590 ( Figure 6A ) in GC samples (n = 315) was determined, by which the patients were classified into 2 groups: miR-590 high expression and miR-590 low expression ( Figure 6B ). ROC curve was drawn to assess the sensitivity and specificity of miR-590 expression in GC, which indicated that the AUC, sensitivity and specificity of miR-590 were respectively 0.53, 19.7% and 91.6% ( Figure 6A ), suggesting that miR-590 expression might be a potential marker for GC patients. Furthermore, we found that miR-590 expression had no association with the age, gender, pathological stage and TNM stage (each P > .05, Table S4 ).
Kaplan-Meier analysis referred that the patients with miR-590 high expression presented higher tumour recurrence rate, but had no significant difference in OS compared with those with miR-590 low expression ( Figure 6C) . Nevertheless, the patients of early stage (stage I+II) or late stage (stage III+IV) with miR-590 high expression exhibited no difference in tumour recurrence compared with those with miR-590 low expression ( Figure S4 ). Multivariate analyses illustrated that, miR-590 expression as well as gender was an independent prognostic factor for tumour recurrence of GC patients (Table S5 ).
| D ISCUSS I ON
Some studies have shown that PPM1F expression is upregulated in HCC and breast cancer 9, 14, 15 and participates in tumour cell motility and invasion. [5] [6] [7] [8] [9] But, the association between PPM1F expression and the clinicopathological characteristics and prognosis of these patients is not elucidated. In our study, inconsistent with the with GC in a large sample size from TCGA data. Multivariate analysis revealed PPM1F as an independent prognostic factor for tumour recurrence of GC patients. Our results were sustained by another report indicating that PPM1F low expression is related to distant metastasis and poor survival of lung cancer. 23 These findings suggested that loss of PPM1F might be involved in the GC tumorigenesis.
To further reveal the reason for PPM1F downregulation in GC, we found no significant alterations in genetic and epigenetic dysregulation of PPM1F in GC. Then, we attempted to predict 5 miRNAs These results implied that the aberrant expression of PPM1F in GC might be caused by the dysregulation of miRNAs.
Functionally, contrary with previous reports, [5] [6] [7] [8] [9] we found that PPM1F overexpression suppressed cell proliferation and invasion and counteracted the tumour-promoting role of miR-590, but PPM1F knockdown reversed these effects. Multivariate analysis also revealed miR-590 as an independent prognostic factor for tumour recurrence of GC patients. Intriguingly, our findings for the functions of miR-590 in GC were also supported by some other studies in a variety of cancers, such as colorectal cancer (CRC), 24 cervical cancer 25 and glioblastoma, 26 but opposed by those in CRC 27, 28 and glioblastoma multiforme. 29 Thus, our above results showed that miR-590 might act as an oncogenic marker in GC by targeting PPM1F.
| CON CLUS IONS
Taken together, PPM1F expression was downregulated, but miR-590 was upregulated in GC samples and their expression levels were correlated with tumour recurrence of the patients with GC. miR-590 was further identified to exhibit an oncogenic role by targeting PPM1F and acted as an independent prognostic factor for tumour recurrence of GC patients. À
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